1430844-80-6
1430844-80-6 structure
- Name: A-1331852
- Chemical Name: A-1331852
- CAS Number: 1430844-80-6
- Molecular Formula: C38H38N6O3S
- Molecular Weight: 658.812
- Catalog: Signaling Pathways Apoptosis Bcl-2 Family
- Create Date: 2018-04-09 21:17:07
- Modify Date: 2024-01-04 12:06:47
-
A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM.
| Name | A-1331852 |
|---|---|
| Synonyms |
2-Pyridinecarboxylic acid, 6-[8-[(2-benzothiazolylamino)carbonyl]-3,4-dihydro-2(1H)-isoquinolinyl]-3-[5-methyl-1-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-1H-pyrazol-4-yl]-
3-[1-(Adamantan-1-ylmethyl)-5-methyl-1H-pyrazol-4-yl]-6-[8-(1,3-benzothiazol-2-ylcarbamoyl)-3,4-dihydro-2(1H)-isoquinolinyl]-2-pyridinecarboxylic acid |
| Description | A-1331852 is an orally available BCL-XL selective inhibitor with a Ki of less than 10 pM. |
|---|---|
| Related Catalog | |
| Target |
Bcl-xL:0.01 nM (Ki) Bcl-W:4 nM (Ki) Bcl-2:6 nM (Ki) Mcl-1:142 nM (Ki) |
| In Vitro | A-1331852 selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells with IC50s in the low nanomolar range but does not affect MEF cells lacking BAK or BAX. In CellTiter-Glo cell viability assay, A-1331852 inhibits NCI-H847, NCI-H1417, SET-2, HEL, OCI-M2 with EC50 values of 3, 7, 80, 120 and 100 nM[1]. |
| In Vivo | A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent. Additionally, A-1331852 combines with venetoclax to recapitulate the efficacy of navitoclax in the NCI-H1963.FP5 xenograft model of SCLC. A-1331852 significantly inhibits tumor growth in seven subcutaneous xenograft models of solid tumors, including breast cancer, NSCLC, and ovarian cancer[1]. |
| Cell Assay | SCLC and AML cell lines are incubated with increasing concentrations of navitoclax, venetoclax, or A-1155463 for 48 hours before assessing cell viability. Cell killing EC50 values are calculated[1]. |
| Animal Admin | Mice: The growth inhibition of established tumors in SCID-bg mice is studied. A-1331852 is administered orally daily for 14 days at 25 mg/kg and docetaxel is administered intravenously at 7.5 mg/kg. The change of tumor volume is monitored daily[1]. |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Molecular Formula | C38H38N6O3S |
| Molecular Weight | 658.812 |
| Exact Mass | 658.272583 |
| LogP | 6.67 |
| Index of Refraction | 1.792 |
| Storage condition | -20℃ |